Chloe E. Atreya, MD, PhD
Combination immunotherapy has shown great promise in patients with metastatic colorectal cancer (mCRC), specifically in the CheckMate-142 study in which nivolumab (Opdivo) plus ipilimumab (Yervoy) yielded a 55% overall response rate and 80% disease control rate in patients with DNA mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC).
State of the Science Summit™ on Gastrointestinal Cancers, Atreya, an assistant clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discussed the latest treatment advances in mCRC, including tumor sidedness and emerging immunotherapy strategies.
OncLive: What are some recent developments in the mCRC landscape?
I focused on sidedness and maintenance strategies for specific subgroups, including patients with MSI-H and BRAF-
mutated CRC. With sidedness, I gave an overview of recent research, including Study 80405. I highlighted the NCCN guidelines, which state that EGFR-targeted antibodies are an option for patients with left-sided RAS
wild-type tumors. These antibodies should not be considered for patients who have RAS-
mutated tumors or right-sided tumors in the first-line setting.
-mutated tumors, the recent NCCN guidelines now include the strategy of irinotecan and cetuximab (Erbitux) with or without vemurafenib (Zelboraf) as a potential option for patients in the second-line setting. Although it is not FDA approved, its inclusion in the NCCN guidelines will make it more available for these patients to receive vemurafenib.
Where is the field in terms of research on tumor sidedness?
Initially, there were a lot of questions about whether or not sidedness was just something related to tumor burden or prognostic and potentially predictive mutations. Now we know that sidedness is an independent prognostic factor.
... to read the full story